Drug Trial Radar · NCT01871805
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Sep 30, 2013
Primary completion
Oct 24, 2014
Study completion Aug 31, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will receive the recommended phase II dose.
Conditions
- Non-Small Cell Lung Cancer
Interventions
AlectinibDrug
Participants will receive alectinib as described in the arm descriptions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs): Phase ITime frame: Throughout Cycle 1 of Phase I (21 days)
- Recommended Phase II Dose (RP2D): Phase ITime frame: Throughout Cycle 1 of Phase I (21 days)
- Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase IITime frame: Cycle 1 Day 1 up to 194 weeks (assessed at every 6 weeks from Cycle 1 Day 1, at Cycles 2, 4, and 6 between Days 14-21, and every 3 cycles thereafter) (1 cycle = 21 days)
Locations
42 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California Irvine
Irvine, California
UCSD Moores Cancer Center
La Jolla, California
Loma Linda Cancer Center
Loma Linda, California
UCLA
Los Angeles, California
Univ of Colorado Canc Ctr
Aurora, Colorado
National Jewish Health
Denver, Colorado
Lynn Regional Cancer Center West
Boca Raton, Florida
Florida Hospital Cancer Inst
Orlando, Florida
UF Health Orlando
Orlando, Florida
H. Lee Moffitt Cancer Center and Research Inst.
Tampa, Florida
University of Illinois Cancer Center
Chicago, Illinois
Monroe Medical Associates; Ingalls Memorial Hosp
Harvey, Illinois
Massachussets General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Can Ins
Boston, Massachusetts
Newton-Wellesley Hospital
Newton, Massachusetts
St. Joseph Mercy Hospital; Cancer Care Center.
Ann Arbor, Michigan
Wayne State Uni ; Karmanos Cancer Center
Detroit, Michigan
Hackensack Univ Med Ctr
Hackensack, New Jersey
Roswell Park Cancer Inst.
Buffalo, New York
Memorial Sloan-Kettering Cancer Center
Commack, New York
Richmond University Medical Center; Pharmacy Department
Staten Island, New York
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Gabrail Cancer Center
Canton, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Providence Portland Med Ctr
Portland, Oregon
Oregon Health & Science Uni
Portland, Oregon
St. Luke's Hospital; Pharmacy Department
Bethlehem, Pennsylvania
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Cancer Pavillion
Pittsburgh, Pennsylvania
MUSC Hollings Cancer Center
Charleston, South Carolina
Center for Biomedical Research LLC
Knoxville, Tennessee
Texas Oncology-Baylor Sammons Cancer Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Swedish Cancer Inst.
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Cross Cancer Institute
Edmonton, Alberta, Canada
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.